Enveric researchers have been focused on synthesizing novel small molecule therapeutics that leverage a combination approach of synthetic chemistry and synthetic biology.
Enveric has adopted an agnostic approach to synthesis resulting in the creation of a proprietary library, the Psybrary™, which contains a large and diverse portfolio of drug candidates encompassing significant structural diversity and exhibiting therapeutically relevant neuroactive properties. The Psybrary™ includes 15 patent families.
To date, several hundred new chemical entities have been synthesized.
Enveric’s Psybrary™ has given rise to the EVM201 Series, next generation synthetic psilocybin analogues that are considered prodrugs of the active metabolite—psilocin. Enveric’s has completed screening and characterization of its portfolio of psilocin prodrugs, comprised of nine distinct classes. All molecules were rationally designed to achieve altered metabolic and pharmacokinetic properties with the intention of improving the drug-like properties and pharmacological profile of EVM201 drug candidates compared to the natural compound, psilocybin.
These next-generation compounds aim to improve the patient’s therapeutic response, while minimizing side effects.
Enveric’s third generation of therapeutics are intended to offer a holistic approach for treating central nervous system disorders. The EVM301 Series is progressing through early discovery and characterization efforts, utilizing proven strategies and tools to accelerate the activities for defining additional promising neuroactive drug candidates.
